Fig. 1From: The clinical outcome of Dienogest treatment followed by in vitro fertilization and embryo transfer in infertile women with endometriosisSchematic representation of the study protocol for the DNG group and control groupIn the control group, patients received standard controlled ovarian hyperstimulation with mid-luteal phase GnRH agonist down-regulation. Nasal spray GnRH agonist was administered from the mid-luteal phase in the previous cycle to the time of HCG injection for the ovulation induction of the IVF-ET cycle. Controlled ovarian hyperstimulation was initiated from the second day of the IVF-ET cycle by FSH and HMG. In the DNG group, DNG was administered orally every day for 12 weeks from 3 months prior to the IVF-ET cycle. Withdrawal bleeding was induced using E and P. Controlled ovarian hyperstimulation was given in a manner similar to that in the control group. GnRH agonist: buserelin acetate 900 mg/day; E: conjugated estrogen; P: dydrogesterone; M: menstruation; FSH: follicle-stimulating hormone; HMG: human menopausal gonadotropin; HCG: human chorionic gonadotropin; OPU: ovum pick-up; DNG: dienogest; dinagest, 2 mg/day.Back to article page